GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Classificação em ações
#3633
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Preço da ação
$27.54
Última sincronização: 2026-10-19
Valor de mercado
$4.67B
Variação (1 dia)
-2.73%
Variação (1 ano)
-11.86%
País
IN
Negociar GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Categoria
Healthcare
EPS de GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
EPS em June 2026 TTM: $0.70
De acordo com os últimos relatórios financeiros e o preço das ações da GlaxoSmithKline Pharmaceuticals Limited, o EPS atual da empresa (TTM) é $0.70. No final de 2024, a empresa teve um EPS de $0.42, uma diminuição em relação a ao EPS de 2023, que foi de $0.44.
Histórico de EPS da GlaxoSmithKline Pharmaceuticals Limited de 2004 até 2026
EPS no final de cada ano
| Ano | EPS | Alterar |
|---|---|---|
| 2026 (TTM) | $0.70 | 8.72% |
| 2025 | $0.64 | 53.29% |
| 2024 | $0.42 | -4.31% |
| 2023 | $0.44 | 55.78% |
| 2022 | $0.28 | 20.93% |
| 2021 | $0.23 | 217.40% |
| 2020 | $0.07 | -80.72% |
| 2019 | $0.38 | 19.09% |
| 2018 | $0.32 | 3.69% |
| 2017 | $0.31 | -8.50% |
| 2016 | $0.34 | -7.07% |
| 2015 | $0.36 | -0.91% |
| 2013 | $0.36 | -39.74% |
| 2012 | $0.60 | 26.71% |
| 2011 | $0.48 | -35.63% |
| 2010 | $0.74 | 14.81% |
| 2009 | $0.64 | -10.33% |
| 2008 | $0.72 | -12.43% |
| 2007 | $0.82 | 11.92% |
| 2006 | $0.73 | 11.91% |
| 2005 | $0.66 | 47.32% |
| 2004 | $0.45 | 0.00% |
EPS de empresas semelhantes ou concorrentes
| Empresa | EPS | Diferença de EPS | País |
|---|---|---|---|
| $29.89 | 4,195.77% |
US
|
|
| $6.60 | 848.55% |
US
|
|
| $3.55 | 410.20% |
US
|
|
| $1.26 | 81.09% |
US
|
|
| $20.39 | 2,830.30% |
CH
|
